Otsuka Pharmaceutical has made a Japanese regulatory submission for the approval of Abilify (aripiprazole) for the treatment of manic symptoms associated with bipolar disorder.
The filing is for use only in adult patients, the firm told Scrip. In the US, the atypical antipsychotic was...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?